Fennec Pharmaceuticals Inc.

Good morning, ladies and gentlemen, and welcome to the Finnex Pharmaceuticals First Quarter 2026 Earnings and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions on how to participate will be given at that time. As a reminder, today's conference call is being recorded. I would now like to turn the conference over to Finnex Chief Financial Officer Robert Andrade. Please begin.

Thank you, Operator. And good morning, everyone. Thank you for joining us. We are pleased to host Fennec Pharmaceuticals' first quarter 2026 earnings conference call today, during which we will review our financial results as well as provide a general business update. Joining me from Fennec this morning is our Chief Executive Officer and Board Member, Jeff Hackman. I am also pleased to welcome our Chief Commercial Officer, Terry Evans. who is joining our earnings call for the first time. Terry is a seasoned commercial and operations leader with a proven track record for delivering significant revenue growth and leading high-performing teams. Terry's industry experience spans all facets of commercial operations, including sales, sales management, operations, market access, trade, specialty pharmacy, and data analytics. He has more than 25 years of commercial leadership experience with companies including Curex Pharmaceuticals, Horizon Therapeutics, and Medicis. Since joining Fennec in the fourth quarter of 2024, Terry has played a pivotal role in reshaping and strengthening our commercial organization. He has helped to sharpen our execution, enhance our field presence, and position the team to capitalize on the opportunities ahead. Later in the call, Terry will speak to how recent efforts will support Fennec's next phase of growth. Additionally, our Chief Medical Officer, Dr. Pierre Sayad, will join us for the Q&A portion of today's call. Before we begin, I would like to remind you that during this call, the company will be making forward-looking statements that are subject to risk and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements. References to these risks and uncertainties are made in today's press release and disclosed in the company's periodic and current event filings with the United States Securities and Exchange Commission. In addition, any forward-looking statements made on this call represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements. This conference call is being recorded for audio rebroadcast on Fennec's website, www.fennecpharma.com, where it will be available for the next 30 days. I will now turn the call over to Jeff Hackman.

Thank you, Robert, and good morning, everyone. Thanks for joining the call here today. We are encouraged by our strong start to the year and believe 2026 is a defining period for Fennec. Our conviction is rooted in the progress across many multiple fronts. We've made important strategic enhancements to our business for 2026 that are strengthening our execution across the organization and positions us to continue to build momentum as the year unfolds on the commercial front. we're seeing encouraging early indicators, including positive experiences through our full-service patient support program, FENIC Hears, as well as trends that support our confidence in the opportunity ahead, and Terry will provide more color on those dynamics shortly. Beyond commercial execution, we continue to be encouraged by growing clinical interest in PITMARC and its broader potential. We are pleased to have recently announced a third investigator-initiated study with the University of Arizona Cancer Center to evaluate pedmark in adolescent and young adults, or AYA, and adult patients in head and neck and testicular cancers receiving cisplatin. The news follows recent initiations of two other institution-led clinical studies with Tampa General Hospital, Cancer Institute, and City of Hope. We believe that the data insights generated through these studies and others to come will help support broader clinical adoption of PEDMARC to prevent ototoxicity in AYA and adult cancer patients receiving cisplatin-based treatments. Additionally, four abstracts from key opinion leaders evaluating the utility of PEDMARC in preventing cisplatin-induced ototoxicity or permanent hearing loss were accepted for the presentation at this year's ASCO annual meeting. Collectively, these studies are continuing to the momentum and the growing body of evidence supporting potential use of Pedmark in new patient populations and tumor types. As a reminder, Pedmark is currently approved for pediatric patients one month of age and older with localized non-metastatic solid tumors and is also recognized by the National Cancer or National Comprehensive Cancer Network with a 2A recommendation for use in AYA patients. With regards to Japan, we had a positive informal PMDA meeting earlier this quarter. We continue to be in conversations and to explore partnering opportunities in that region. So, in summary, We're making meaningful progress across the drivers that matters most to our long-term success, expanding clinical momentum, strengthening commercial execution, and maintaining a solid financial foundation. Taken together with what we are observing early in Q2, we believe we are well-positioned to deliver sustained growth throughout this year. With that, I will turn it over to Terry for a detailed commercial update.